What analysts say:
- Buy, sell, or hold?: Analysts strongly back Allscripts, with 18 of 21 rating it a buy and the remainder rating it a hold. Analysts like Allscripts better than competitor athenahealth overall. Analysts still rate the stock a moderate buy, but they are a bit more wary about it compared to three months ago.
- Revenue Forecasts: On average, analysts predict $379.6 million in revenue this quarter. That would represent a rise of 12.6% from the year-ago quarter.
- Wall Street Earnings Expectations: The average analyst estimate is earnings of $0.21 per share. Estimates range from $0.19 to $0.23.
What our community says:
CAPS All-Stars are enthusiastically backing the stock, with 97.7% assigning it an "outperform" rating. Most of the community is in line with the All-Stars, with 95.2% awarding it a rating of "outperform." Fools feel positively about Allscripts and haven't been shy with their opinions lately, logging 223 posts in the past 30 days. Even with a robust four out of five stars, Allscripts' CAPS rating falls a little short of the community's upbeat outlook.
The company's gross margin shrank by 673.9 percentage points in the last quarter. Revenue fell 7704.9% while cost of sales rose 572% to $201.8 million from a year earlier.
For all our Allscripts-specific analysis, including earnings and beyond, add Allscripts to My Watchlist.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.